Pfizer completes acquisition of two GSK meningitis vaccines

In a move to ease antitrust concerns ahead of its multibillion-dollar asset swap with Novartis ($NVS), GlaxoSmithKline ($GSK) announced in June that it would sell two of its mature meningitis jabs to Pfizer ($PFE). The $130 million acquisition of Mencevax and Nimenrix has now closed. Both are marketed outside the U.S. and target the A, C, Y and W strains, but not the B strain. More

Suggested Articles

The U.K.'s two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses while expanding clinical trials.

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.